(PDF) Pcn305 - Nice and the Cancer Drugs Fund – Can

Pcn305 - Nice and the Cancer Drugs Fund – Can Observational Evidence Inform Funding Decisions in Oncology?

Value in Health - United Kingdom

doi 10.1016/j.jval.2018.09.387

Full Text

Abstract

Available in full text

Categories

Occupational Health

Date

October 1, 2018

Authors

Publisher

Elsevier BV

Related search

Pcn239 - Nice and the Cancer Drugs Fund: Appraising Treatments for Rarer Cancers in England

Value in Health

Occupational Health

English

Informing Canada’s Cancer Drug Funding Decisions With Scientific Evidence and Patient Perspectives: The Pan-Canadian Oncology Drug Review

Current Oncology

English

Reimbursement Decisions in Oncology Drugs: An International Analysis

Value in Health

Occupational Health

English

Pcn230 - Are Nice and the SMC Diverging in Their Assessment of Oncology Drugs?

Value in Health

Occupational Health

English

Pcn312 - How Has the Relaunched Cancer Drugs Fund Affected Nice’s Approval of Novel Oncology Technologies?

Value in Health

Occupational Health

English

PCN163 Funding by SHAs for Rarer Cancers in England: Key Success Factors in the Uptake of Cancer Drugs Fund

Value in Health

Occupational Health

English

Pcn292 - Cancer Drugs in Germany: Hta Decisions of New and Innovative Oncology Drugs in Germany – An Analysis Using the Prismaccess® Database

Value in Health

Occupational Health

English

Pcn43 - A Targeted Review of Nice Single Technology Appraisals (Stas) in Urothelial Cancer Since the Introduction of the New Cancer Drugs Fund (Cdf)

Value in Health

Occupational Health

English

Pcn302 - Is the New Nice Appraisal Process for Oncology Indications Too Positive in Its Assessment of Cancer Drugs in England?

Value in Health

Occupational Health

English